Is amiloride a promising cardiovascular medication to persist in the COVID-19 crisis?

Mir S Adil1, S Priya Narayanan1, Payaningal R Somanath1

  • 1Clinical and Experimental Therapeutics, University of Georgia and Charlie Norwood VA Medical Center, Augusta, GA, USA.

Insights

Amiloride may be an ideal COVID-19 treatment due to its effects on angiotensin-converting enzyme (ACE) and cytosolic pH. This drug offers a promising alternative or add-on therapy for patients, potentially improving outcomes.

Area of Science:

  • Pharmacology
  • Virology
  • Cardiovascular Medicine

Background:

  • The COVID-19 pandemic necessitates evidence-based therapeutic strategies.
  • Patients with hypertension and diabetes using ACE inhibitors face uncertainty regarding SARS-CoV-2.
  • ACE inhibitors may increase ACE2, facilitating SARS-CoV-2 entry.

Purpose of the Study:

  • To evaluate amiloride as a potential therapeutic agent for COVID-19.
  • To explore amiloride's effects on ACE levels and cytosolic pH in the context of COVID-19.

Main Methods:

  • Review of existing literature on amiloride's pharmacological properties.
  • Analysis of amiloride's potential interactions with SARS-CoV-2 mechanisms.
  • Assessment of amiloride's known effects on ACE and pH.

Main Results:

  • Amiloride demonstrates potential to reduce ACE levels.
  • Amiloride increases cytosolic pH, a beneficial effect.
  • Its potassium-sparing and anti-epileptic properties are noted.

Conclusions:

  • Amiloride presents a promising candidate for COVID-19 treatment.
  • It may serve as an alternative or combinatorial therapy.
  • Further research is warranted to validate its efficacy and safety in COVID-19 patients.

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
705
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
115
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
647
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
1.3K
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
984
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
169